
Zoetis Inc.
Zoetis Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $32.8B. Its FinScore is 67/100; its highest-scoring layer is Quality (91) and its lowest is Growth (30). The shares trade at 12.5x trailing earnings and are down 37% year to date.
Share price performance
About Zoetis Inc.
www.zoetis.comZoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 73 days ago
- Market cap
- $32.8B
- Shares outstanding
- 413.2M
- P/E (TTM)
- 12.5x
- Dividend yield (TTM)
- 2.63%
- Beta (issuer)
- 0.74
- Revenue (latest FY)
- $9.5B
Revenue breakdown
- Horses67.8%$6.3B
- Cattle16.1%$1.5B
- Swine5.0%$466.0M
- Poultry4.7%$432.0M
- Dogs and Cats3.3%$304.0M
- Fish3.1%$286.0M
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Zoetis Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.